ERNA icon

Eterna Therapeutics

1.18 USD
-0.11
8.53%
At close Updated Sep 15, 4:00 PM EDT
Pre-market
After hours
1.26
+0.08
6.78%
1 day
-8.53%
5 days
-6.35%
1 month
-25.79%
3 months
-50.63%
6 months
-71.29%
Year to date
-78.7%
1 year
-94.79%
5 years
-99.88%
10 years
-99.98%
 

About: Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.

Employees: 6

0
Funds holding %
of 7,463 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0.49% more ownership

Funds ownership: 0.19% [Q1] → 0.68% (+0.49%) [Q2]

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

54% less funds holding

Funds holding: 26 [Q1] → 12 (-14) [Q2]

65% less capital invested

Capital invested by funds: $264K [Q1] → $91.7K (-$173K) [Q2]

93% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 15

Financial journalist opinion

Neutral
GlobeNewsWire
5 days ago
Ernexa Therapeutics Provides Update on Operational Excellence and Performance
CAMBRIDGE, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today provided an update on its operational excellence and performance for the first half of 2025.
Ernexa Therapeutics Provides Update on Operational Excellence and Performance
Neutral
GlobeNewsWire
12 days ago
Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will be featured as a presenting company at the H.C. Wainwright 27th Annual Global Investment Conference , being held September 8–10, 2025.
Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference
Neutral
GlobeNewsWire
2 months ago
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
CAMBRIDGE, Mass., July 09, 2025 (GLOBE NEWSWIRE) --   Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market.
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements
Neutral
GlobeNewsWire
2 months ago
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa's Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa's Strategic Focus on Ovarian Cancer and Autoimmune Disease Programs
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
Neutral
GlobeNewsWire
2 months ago
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives Stockholder-approved financing brings total gross proceeds to $7.1 million; funds to support working capital initiatives
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement
Neutral
GlobeNewsWire
3 months ago
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share (the “Common Stock”), at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company's Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.”
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
Neutral
GlobeNewsWire
3 months ago
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes New data finds novel cell therapy successfully converts “cold” ovarian tumors into “hot,” demonstrating potential to unlock immune response and improve outcomes
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
Neutral
GlobeNewsWire
4 months ago
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the formation of ErnexaTX2, a wholly owned subsidiary based in Texas.
Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations
Neutral
Newsfile Corp
4 months ago
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference
Cambridge, Massachusetts--(Newsfile Corp. - May 8, 2025) - Ernexa Therapeutics (NASDAQ: ERNA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City.
Ernexa Therapeutics Announces Participation in the D. Boral Capital Inaugural Global Conference
Neutral
GlobeNewsWire
4 months ago
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
CAMBRIDGE, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, presented noteworthy new data at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago on April 28.
Ernexa Therapeutics Presented Promising Data on Innovative Cell Therapy Treatment at AACR Annual Meeting 2025
Charts implemented using Lightweight Charts™